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ABSTRACT
Glycine is an important inhibitory neurotransmitter that is localized in the caudal areas of
the nervous system and plays an important role in mediating many important functions related to
breathing, spinal reflexes, nociception etc. Termination of neurotransmission is achieved by the
re-uptake of glycine back into the pre- synaptic neuron and neighboring glial cells by the two
glycine transporters namely Glycine transporter 1 (GlyT1) and Glycine transporter 2 (GlyT2).
These transporters play an essential role in regulating glycinergic inhibition in the central
nervous system by controlling the duration and intensity of neurotransmission and therefore the
efficacy of synaptic inhibition as well.
The GlyTs share 50 % amino acid sequence identity and similar topology; however,
unique to GlyT2 is the presence of a 200-amino acid long N-terminal tail which is not present in
any other related transporter such as the monoamine or GABA transporters, and its functional
aspects have not been explored to date. The importance of this N- terminal domain can be
gauged from the fact that many individuals diagnosed with sporadic Hyperekplexia, a
neurological disorder characterized by excessive startle response, carry point, nonsense and
frameshift mutations along the GlyT2 sequence, including the N-terminal domain (Davies,
Chung et al. 2010). The aim of this research is to understand the role of this N-terminal domain
of GlyT2 in regulating the function and anchorage of the transporter and to study its expression
in the glycine- rich areas of the nervous system like the brainstem, cerebellum and the spinal
cord. This is accomplished by performing Yeast Two Hybrid assay in order to identify proteins
that could interact with the N- terminal domain of GlyT2. Out of the 74 clones identified in the
screen, the first 26 proteins have been identified and are mainly cytoskeletal proteins as well as
some involved in signaling cascades, thus hinting at the important role of the N- terminal domain
vi

of GlyT2 in anchoring the protein at the plasma membrane and perhaps, influencing its
functioning at the glycinergic synapse.
Although it is well known that GlyT2 is abundant in the spinal cord and caudal regions of
the CNS, the location of glycinergic nuclei, axonal projections and connections have not been
explored in detail. The efforts to study these neuronal circuits have been limited, due in part, to
the essential function of GlyT2 for survival and the lack of reagents such as highly specific
antibodies. To map the neuronal pathways containing GlyT2, a transgenic mouse was developed
and kindly provided by Dr. H. U. Zeilhofer, University of Erlangen-Nurnberg, Germany
(Zeilhofer et al. (2005) J. Comp. Neurol. 482, 123-41) which expresses the green fluorescent
protein (GFP) under the control of the GlyT2 promoter. Coronal and sagittal sections of the
transgenic mice brains reveal that the majority of GFP signal is localized to the medulla, pons
and midbrain. Several nuclei containing GFP are restricted to the Colliculi and several areas of
the Pons in the brain stem. Consistent with these findings, we have identified several GFP-,
GlyT2- positive neurons in the Central nucleus if the Inferior Colliculus (CIC) and several areas
of the brainstem such as the ventral cochlear nuclei (VCA), and several nuclei which make up
the Superior Olivary Complex (SOC). The existence of GlyT2 in the areas involved in audition
could provide important insights into the importance of glycinergic inhibition in mediating
audition and could possible lead to further research in understanding the important sense of
audition and treat maladies associated with it.
The work described in this thesis has provided insights into the importance of GlyT2 in
mediating glycinergic inhibition and could serve as a foundation to identify glycinergic circuits
in the CNS, which can be manipulated by optogenetic techniques to gain a better understanding
of glycinergic neurotransmission.
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CHAPTER 1: INTRODUCTION.
1.1: Glycine as a neurotransmitter:
Glycine, a non- essential amino acid is an essential inhibitory neurotransmitter in the
central nervous system (CNS). Along with gamma amino butyric acid (GABA), glycine plays an
important role in the maturation of the developing nervous system as well. While GABA is
ubiquitously expressed in the CNS, glycine is predominately localized in the caudal areas of the
nervous system such as brainstem, cerebellum and the spinal cord. During fetal development,
both neurotransmitters are excitatory in nature due to the absence of the Cl-/K+ antiport system
(Eulenberg V, 2005) (Zafra F, 2005). However, after birth, they resume their inhibitory function
with glycine providing immediate inhibition as compared to prolonged inhibitory action by
GABA (Eulenburg V, 2010). Glycine plays an important role in regulating a variety of motor
and sensory functions such as vision, audition, respiration, and nociception and influencing
neural development (Aragón and López-Corcuera 2003; Aragon and Lopez-Corcuera 2005;
Coleman, Fischl et al. 2011) In addition to its inhibitory functions, glycine also plays an
important role in excitatory glutamatergic neurotransmission. It acts as an obligatory co-agonist
for the activation of N-methyl-D-aspartate (NMDA) receptors, which play an important role in
synaptic plasticity and learning and memory (Johnson and Ascher, 1987).

1.2 Role of Neurotransmitter Transporters:
Once a neurotransmitter has been released into the synapse, it needs to be cleared away
rapidly in order to end the signal and to start a new wave of neurotransmission. This is
accomplished by a) the rapid breakdown and recycling of the neurotransmitter into its
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components (e.g. breakdown of acetylcholine by acetylcholinesterase) or b) by mediating the
clearance and reuptake of the neurotransmitter by a special family of proteins known as
‘neurotransmitter transporters’. (Eulenberg V, 2005). These transporters are responsible for the
high affinity uptake of neurotransmitter from the synapse back into the pre- synaptic neurons and
the neighboring glial cells.

Based on their primary structure and the site of action,

neurotransmitter transporters are classified into two super-families namely, the plasma
membrane transporters and the vesicular membrane transporters. The plasma membrane
transporters superfamily can be further divided into two families depending on their ionic
dependence: 1) the Na+/Cl2 -dependent transporters and 2) the Na+/ K+-dependent transporters
(Masson, Sagne et al. 1999). Plasma membrane neurotransmitter transporters, as the name
suggests, are localized exclusively at the plasma membrane. DAT, SERT, NET, GAT1–4, GlyT1
and GlyT2 neurotransmitters transporters belong to the SLC6 gene family transporters (Gether,
Andersen et al. 2006). Several members of the SLC6 transporter family have been implicated in
the development of neurological and psychiatric diseases like drug addiction, depression,
schizophrenia, hyperekplexia etc. (Gether, Andersen et al. 2006), thus making them attractive
targets for the development of novel therapeutic options for the treatment of the above mentioned
complications. Some of the well-known members of the SLC6 superfamily of neurotransmitter
transporters are mentioned in the illustration below:

2
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1.3 Glycine transporters:
The intensity and duration of glycinergic neurotransmission is terminated by the reuptake of glycine back into the presynaptic neuron through the action of two transporters,
glycine transporters 1 and 2 (GlyT1 and GlyT2 respectively), encoded by different genes. These
high-affinity transporters for glycine belong to the Na+/Cl- dependent transporter family SCL6,
and share many structural characteristics found across various members of the SCL 6 family.
(Aragon C, 2003)
Based on the homology modeling and hydropathy analysis, the GlyTs consists of 12
transmembrane domains, a large glycosylated extracellular loop between TM3 and 4, and
intracellular N- and C-terminal tails. Both GlyTs exist in different isoforms: three GlyT2 a, b,
and c, which differ in their amino terminal, and five GlyT1 a, b, and c differing in their amino
terminal and GlyT1d, and e, with differences in the carboxyl terminal (Eulenburg, Armsen et al.
2005). Both transporters are glycosylated at four asparagine (Asn) residues located in the second
large extracellular loop, which triggers the transporter to its cellular location, the plasma
membrane (Gether, Andersen et al. 2006). Figure 1 depicts the membrane topology of glycine
transporters.
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Figure 1: A) Membrane toplogy of Glycine Transporters (GlyTs).
Both transporters show the following common characteristics namely, 12 Transmembrane domains, 6
extra- cellular loops and 5 intracellular loops,
intracellular N & C termini and 4 extracellular glycosylation sites on the second extra- cellular loop.
B) GlyT2 unique aspects: 3 N – terminus isoforms a, b &c have been identifies. The N- terminus shows
presence of extra 201 amino acid, long tail.
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Although GlyT1 and GlyT2 share a 50% sequence identity, they differ in their Nterminus sequence, with GlyT2 having a 200 amino acid long N-terminus of unknown function
(Eulenburg, Armsen et al. 2005).

1.4 Distribution and function of Glycine transporters:
GlyT1 is predominately localized in the glial cells of the brain, with some recent
evidence suggesting that it is also expressed neuronally in certain areas of the brain. GlyT2 on
the other hand, is exclusively neuronal and hence considered to be a marker for glycinergic
synapses. (Eulenberg V, 2005). GlyT1 is predominantly localized in areas such as olfactory
bulbs, cortex, hippocampus, septum and thalamus and hindbrain areas such as brainstem,
cerebellum and spinal cord where GlyT2 is exclusively found as well. This expression profile
indicates that despite the complementary role of both transporters, in removing glycine, there are
subtle differences in the way they achieve this goal. GlyT2 is predominantly responsible for
glycine uptake at glycinergic synapses, whereas GlyT1 is involved in clearance of glycine from
the synapse into adjacent glial cells and monitoring glycine concentration in the vicinity of
NMDA receptor expressing synapses.

1.5 Glycine transporter 2:
GlyT2 is found to be expressed exclusively in glycinergic neurons of the brain stem and
spinal cord where it is chiefly responsible for mediating the efficient removal of extracellular
glycine from the synaptic cleft and its repackaging into the glycinergic synaptic vesicles. Thus
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GlyT2 is considered as a marker for glycinergic inhibitory circuits. (Eulenburg, Armsen et al.
2005).
Despite widespread structural homology between GlyT2 and GlyT1 and other members
of the Na+/Cl- dependent transporter family, a unique characteristic of the GlyT2 is the presence
of a long N- terminal tail consisting of about 201 amino acids, not found in any other neuronal
transporter protein. BLAST analysis of the GlyT2 N-terminal domain or shorter amino acid
segments against the Swiss-Prot database did not identify any related sequence published to date,
thus confirming that this domain is unique to GlyT2 and might play an important role in its
function/or structure. (See Figure 2)
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Figure 2: A) GlyT2 topology: The N and C- termini are intracellular, The N- terminus shows an extra 201
amino acid tails.
Differential splicing of GlyT2 gene gives rise to 3 known isoforms- GlyT2 a, GlyT2 b and GlyT2 C.
Mutations in the N- terminus tail amino acids is linked to Sporadic Hyperkplexia in humans.
B) GlyT2 deficient mice show poor growth and reflexes.
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The importance of GlyT2 can be validated by the fact that frameshift mutations and
micro-deletions along the GlyT2 sequence, including in the N-terminus of the GlyT2 gene results
in the development of Hyperekplexia or Startle Disease, a neurological disorder characterized by
exaggerated startle response to noise or touch stimuli, non-epileptic seizures, muscle weakness
and stiffening (Davies, Chung et al. 2010) (Harvey R, 2008). Deletion of GlyT2 in neonatal mice
leads to symptoms like difficulty in breathing, muscle stiffness, and an exaggerated startle
response to stimuli followed by death within two weeks (Gomeza. J, 2003). All these features
highlight the importance of GlyT2 in maintaining important sensory and motor functions by
influencing glycinergic neutransmission. Interestingly, GlyT2 appears to be unique to chordates
whereas GlyT1 is present in non-chordates as well, suggesting that GlyT2 is required for
regulation of functions that evolved quite later in evolution.
Although GlyT2 structure and function are critical for animal survival and proper
neurotransmission, very little effort has been dedicated to understanding its unique aspects or
function at the pre-synaptic neuronal plasma membrane.
It has been reported that GlyT2 is predominantly localized in glycinergic neurons which
are abundantly found in the caudal areas of the central nervous system like the brainstem,
cerebellum and the spinal cord ((Zafra, Aragon et al. 1995). However, there are no studies which
conclusively reveal the location of glycinergic cell bodies in the caudal areas of the brain nor is
there any mention of the axonal projections of these glycinergic neurons and the connections
they make throughout the brain to modulate important sensory and motor functions. Unlike the
well-established neuronal projections of the dopaminergic and serotonergic cell bodies in the
substantia niagra, ventral tegmental area (VTA) and the brainstem respectively, there seems to be
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no mention of a glycinergic circuit and its projections. The efforts to study these glycinergic
circuits have been limited by technical issues such as a lack of reagents including highly specific
antibodies against glycinergic markers. The identification of these glycinergic circuits in the
brain would pave the way in understanding the role of glycine and GlyT2 in mediating important
sensory and motor functions like breathing, pain perception, and spinal reflexes.
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1.6 Specific Aim of the Research:
The overall aim of this research is to develop a better understanding of GlyT2 and in
order to accomplish this objective I have chosen to focus on the following two aspects:
Specific Aim 1: To identify proteins interacting with the N-terminal domain of the
GlyT2.: The working hypothesis of this project is that the unusually long tail of N-terminus
could play a crucial role in regulating the function and anchorage of the transporter by
serving as a binding site for a number of cytoskeletal proteins or proteins involved in
signaling pathways. A large number of proteins have been identified that interact with the Nterminus of DAT, NET or SERT including different kinases, receptor and scaffolding
proteins either to modulate the activity or regulate their trafficking and degradation (Lee,
Kim et al. 2004; Eriksen, Jørgensen et al. 2010; Sager and Torres 2011). Studies have been
published that reveal the presence of certain proteins like syntaxin-1 that interact with the
carboxy terminus of the GlyT2 and facilitate its localization at the pre-synaptic membrane
(Ohno, Koroll et al. 2004; Armsen, Himmel et al. 2007). In contrast, to date, the only protein
so far identified and reported to interact with the GlyT2 N-terminal domain is the Ulip6, a
member of the collapsin response mediator protein family with unknown function. (Horiuchi,
El Far et al. 2000; Horiuchi, Loebrich et al. 2005). Although Ulip6 was shown to coimmunoprecipitate with GlyT2, immunocytochemical analysis failed to show co-localization
of Ulip6 with GlyT2 in neuronal primary cultures or shed any light on its possible role in
modulating GlyT2 function or anchorage at the presynaptic membrane. Moreover, there
seems to be no information about the exact role of Ulip6 in mediating GlyT2 activity.
Hence, the objective of this project is to identify a wide variety of proteins interacting
with the N-terminus of GlyT2 which would provide new insights into the role played by
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these interacting proteins in the anchorage of the transporter and any possible role in
influencing its functioning at the presynaptic membrane.

Specific Aim 2: To identify GlyT2 expression in the glycine- rich areas of the
central nervous system and glycinergic cell bodies and their projections: While it has been
known that GlyT2 is found exclusively in the presynaptic nerve terminals of glycinergic
neurons, there have been no studies done in order to identify the location of these glycinergic
nuclei, axonal projections and connections in the brain. The identification of these
glycinergic circuits in the brain would pave the way in understanding the role of glycine and
GlyT2 in mediating important sensory and motor functions.
Therefore, the objective of this aim is to map the glycinergic circuits in mouse brain,
to identify the cell bodies and their projections in the glycine-rich areas of the brain such as
the brainstem, cerebellum and the spinal cord and to confirm the localization of GlyT2 in
these glycinergic circuits.
The forthcoming chapters elaborate upon the experimental methodology adopted to
accomplish these research aims, the results of the experiments, and a detailed discussion
about the findings of this research as a conclusion.

12

CHAPTER 2: RESULTS
2.1: Results for Specific aim 1:
In order to accomplish the first specific aim of the project, I decided to adopt a genetic
approach by performing the Yeast Two- Hybrid screening protocol to identify potential
interacting partners of the N- terminus tail of GlyT2.
2.1.1 Yeast two hybrid assay: Yeast two-hybrid (Y2H) system provides a sensitive
method for detecting relatively weak and transient protein interactions. The Y2H is a sensitive
genetic in vivo assay that allows for identification of novel interactions from complex libraries
and analysis of interaction between known proteins. The assay was developed by Fields and
Song (1989) by exploiting the modular nature of the eukaryotic transcription factors, specifically
the yeast Gal4 protein and the relative ease in using a simple eukaryote like Saccharomyces
cerevesiae as a model system.
Principle of Y2H screens:
Briefly, the binding domain is a portion (domain) of the transcription factor that binds a
specific sequence of DNA whereas the activation domain (AD) acts as a point of contact for the
transcription machinery to attach and initiate transcription. Hence, transcription of a gene
downstream is initiated only if the binding domain and the activation domain physically interact
with each other. Illustration 2 outlines the basic principle of Yeast Two Hybrid assay.
In a typical Y2H screen, the protein of interest termed as ‘bait’ is fused with the binding
domain of Gal4 while the prey is fused to the activation domain of Gal4 such that the interaction
of the bait-prey would result in reconstitution of the transcription factor thus leading to the
expression of the reporter genes located downstream. The interaction is monitored by either
observing colorimetric reaction with the lac Z gene or by the use of auxotrophic markers (usually
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essential amino acids tryptophan, leucine, histidine, adenine) that allow the growth of yeast in
minimal media. Y2H can be easily automated for high throughput studies of protein interactions
on a genome-wide scale be it simple organism like yeast, phage or even complex mammalian
genomes.

14
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2.1.2 Methodology:
For the experiments, I used the Y2H system to screen a normalized human brain cDNA
library (Clontech Inc.) using the large cytoplasmic N-terminal region of GlyT2 as bait. The
DNA sequence encoding the unique 201 amino acids of the amino terminal of GlyT2 (1- 201)
was amplified by PCR from a plasmid encoding the cDNA sequence. The amplified fragment
was subcloned in frame into the inducible vector pGBKT7 vector and verified by DNA
sequencing. The bait, GlyT2 N terminus amino acids 1-201 was used to screen 3 X 106
normalized clones of the human brain cDNA library in pGADT7T transformed into the yeast
strain AH109.
2.1.3 Control experiments:
Before the actual screening of the library is initiated, it is important check the expression
of the bait protein in the yeast and to ensure that the fusion protein isn’t toxic to the yeast strain.
Accordingly, a series of control experiments were devised to ensure accurate results and to
reduce the number of false positives. As a first step, yeast strain AH109 was transformed with
the bait vector, pGBKT7 + N-terminus of GlyT2 and the empty vector pGBKT7, both of which
contain the C-myc tag. In order to verify the expression of the bait vector a western blot was
performed.
Yeast Protein extraction: The colonies of yeast cells transformed with empty bait vector
and fusion protein (transformed with empty vector were used as negative controls) were picked
from the petri dish and grown overnight in 10 ml of minimal nutrient synthetic media (SD)
overnight until an O.D. of 0.6 to 0.8 was reached. The cells are vortexed and transferred to 50 ml
Yeast Peptone Dextrose media (YPD) and grown overnight at 300C shaking at 220-250 rpm until
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the OD reaches 0.4 to 0.6. The cells are transferred to pre-chilled falcon tubes, centrifuged at
1000 X g, washed and the pellet is re-suspended in TE buffer and placed on ice.
The cells were transferred to a new centrifuge tube to which add 500 μl of lysis buffer
fortified with protease inhibitor cocktail (cracking buffer) and 300 μl of glass beads and vortexed
for 15 minutes. The debris is separated from the pellet by subjecting the centrifuge tubes to
centrifugation at 14000 rpm for 5 minutes at 40C. The supernatant is transferred to a new
centrifuge tube and the process is repeated, if necessary. The protein extract is kept at 4 0C. The
protein content of the sample is quantified using the Bradford method of protein estimation. The
negative control and the fusion protein extract samples are mixed with loading dye, briefly
boiled for 5 minutes and loaded onto an agarose gel, which is run at a 100 V for 3-4 hours in
order to separate the proteins. The proteins are transferred to a nitrocellulose membrane, blocked
with milk in TBST for an hour and incubated with the C- myc antibody and GlyT2 antibody that
recognizes the N- terminus of GlyT2. Shown in Figure 3 is the expression of the bait protein
containing the N-terminus of GlyT2 in the yeast protein extract (~37kDa). This transformed
strain was then used to screen the normalized human brain cDNA library (Clontech Inc.)

17
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Figure 3: western Blot to detect expression of the bait fusion protein. Yeast strain AH 109 was
transformed with a)Plasmid pGBKT7 (Empty vector with C- myc tag) and b) pGBKT753+ NGlyT2 and the yeast protein extract was used to perform western blot using C-myc and GlyT2
antibodies to check for the expression of the bait fusion protein.
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2.1.4 Screening of the cDNA library: As shown in illustration 3, the yeast strain AH
109 is co-transformed with the bait (N-terminus +pGBKT53) along with the prey vector
(normalized cDNA of human brain proteins expressed in pGADT7T). The transformed yeast
strain was plated on low stringency (-Leu/-Trp) plates and high stringency (-Ade/-leu/-Trp/-His)
plates to identify true positive interactions.
Screening Results: Out of the 210 positive colonies obtained on the low stringency (Leu/-Trp) plates, 74 positive clones were obtained on high stringency plates (-Ade/-His/-Leu/Trp). Since the colonies obtained on the high stringency plates have a higher probability of
interacting strongly with the N-terminus of GlyT2, we decided to focus on identifying these
clones. The colonies were picked and allowed to grow on appropriate SD medium (-Ade/-His/Leu/-Trp) and the plasmid was extracted by using the yeast plasmid extraction kit (Clontech).
Each of the purified plasmid was transformed in competent E.coli bacterial cells and recovered
using the Mini- prep plasmid extraction kit (Qiagen). The recovered purified plasmids were sent
for sequencing to decipher their identities. The results obtained for clones 1 to 26 are
summarized in table 1 on page 21:
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Illustration 3: Yeast Two- Hybrid- Library Screening Protocol- a brief
outline.
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Table 1. List of proteins identified in the Y2H screen using N- terminus of GlyT2 as
the bait for screening normalized adult human brain library (Clontech Inc.)
No.

Ascension Number
1.

Description

Unknown proteins

Repetition of Clones
4 (clones: 7, 9, 10,
15)

2.

Homo sapiens
NM_014756.2

3 (clones: 6, 11, 13).

cytoskeleton associated
protein 5 (CKAP5).

3.

Homo sapiens
NM_016841.4

3 (clones: 3,4, 8)

microtubule-associated
protein tau (MAPT).

4.

Homo sapiens tectonic
NM_001143973.1

1(clones:1)

family member 3
(TCTN3) isoform.

5.

Homo sapiens
NM_001172818.1

1 (clone: 12)

phosphoglucomutase-1
(PGM1).

6.

WD repeat-containing
NM_020839.2

protein 48 isoform 3
Hypothetical protein
(Homo sapiens).

21

2 (clones: 2, 14)

7.

Homo sapiens
NM_032972.1

1 (clone: 5)

protocadherin 11- Y
(PCDH 11- Y).

8.

Homo sapiens protein
NM_002828.3

1 (clone: 16)

tyrosine phosphatase,
non-receptor type 2
(PTPN2).

9.

Homo sapiens eukaryotic
NM_005875.2

3 (clone: 19, 20, 24)

translation initiation
factor 1b (eIF1b).

10.
NM_006837.2

PREDICTED: COP9

4 (clone: 21, 23, 25,

signalosome

26)

complex subunit 5.
11.

Homo sapiens KDEL
NM_001100603.1

(Lys-Asp-Glu-Leu)
endoplasmic reticulum
protein retention receptor
2 (KDELR2), transcript
variant 2, mRNA.

22

1 (clone: 22)

The plasmids from clones 1 to 26 were recovered from these transformed yeasts by the
yeast plasmid recovery kit protocol (Clontech Inc). These recovered plasmids were then
transformed in competent E.coli bacterial cells (Agilent technologies, US) and the purified DNA
was sequenced to reveal their identity (Table 1). A BLAST search has revealed that the 26 clones
sequenced so far are mostly cytoskeletal proteins found abundantly in neurons especially in the
presynaptic terminals. Out of the 26, the identity of 4 is not known as no matches were found in
the BLAST database. The remaining 22 proteins remain promising targets for further studies.
As a further step in checking the validity of our results and to identify clones that grow
better (hence indicating better chances of positive interactions), a drop test was performed. Serial
dilutions of clones 1 to 24 were prepared at the following concentrations: 101, 100, 10-1, 10-2 and
plated (10µls) on the low stringency (-Leu/-Trp) and high stringency (-Ade/-His/-Leu/-Trp). The
positive control is the fusion protein of bait pGBKT7 53 and prey pGADT7-T plasmids cotransformed in the yeast AH109 while the negative control is the empty bait vector pGBKT7 53
transformed in yeast AH109.

Figure 4 shows the results of drop test for clones 1 to 24. As

expected all the clones grew well on the low stringency plates, but only a few clones grew well
on both low and high stringency plates (2, 6 and 9 to 16).
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Figure 4: Drop Test: Clones 1 to 24 were diluted at the following dilutions: 10 10 10 10 and plated at a
volume of 100 µl on Low stringency (- Leu/-His) plates (Panel A, C, E) and High stringency plates (- Ade/ Leu/-His/-Trp) plates (Panel B, D, F). Positive Control (+) was the fusion protein of the bait and prey
vectors pGBKT753 and GADT7T co- transformed in Yeast strain AH109. Negative Control (-) is the
empty bait vector. *clones 25 and 26 were not plated due to contamination.
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2.2 Results for Specific aim 2:
2.2.1 Identifying the expression of GlyT2 in the CNS using a transgenic mouse
model.
As mentioned previously, GlyT2 is exclusively glycinergic and is an excellent marker to
identify glycinergic synapses in the CNS. For almost all major neurotransmitters, there exists
abundant information about the cell bodies that produce these neurotransmitters as well as the
areas to which they send their projections. For example, dopaminergic neurons are found in the
substantia niagra whereas serotonergic cell bodies are found in the nucles of Raphe. However,
there isn’t much information in the literature about the existence of exclusively glycinergic cell
bodies or their projections to different areas of the brain. Hence, I decided to address this
question as part of my second specific aim that by trying to identify glycinergic cell bodies in the
glycine-rich areas of the brain such as the brainstem, cerebellum and the spinal cord using a
transgenic mouse model. The information gleaned from this project would be useful in
identifying dedicated glycinergic circuit, which could be manipulated and studied in detail using
optogenetics and electrophysiological techniques.

2.2.2 Experimental design: A transgenic mouse expressing green fluorescent protein
under the control of the GlyT2 promoter was obtained from Dr. H. U. Zeilhofer, University of
Erlangen-Nurnberg, Germany (Zeilhofer et al., 2005) and used for the studies described in this
section. In addition, a highly specific polyclonal antibody against the N-terminus tail of GlyT2,
synthesized and tested for specificity in the Miranda lab was used for all immunostaining
experiments.
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Immunohistochemistry:

For immunohistochemistry, 1 adult transgenic mouse was

deeply anesthetized with nembutal (50 mg/kg; i.p.) and perfused through the ascending aorta
with 4% paraformaldehyde (pH 7.4). The brain was post-fixed, cryo-protected in sucrose and
cut parasaggitally at 30-micrometer section thickness with a sliding microtome (Leica Inc.).
Sections were collected in PBS and stored in an antifreeze solution (15% glucose and 30%
ethylene glycol in 50 mM phosphate buffer, pH 7.4) prior to use. Series of adjacent sections were
mounted to observe the GFP expression by observing the tissue under fluorescent microscope
(Zeiss Inc.) Also, sections next in series were used for performing Nissls staining, that provides
information of the cytoarchitecture of the region and helps locate anatomical landmarks.
2.2.3 Results: Figure 5 represents the first experiment to identify the glycine-rich areas
of the CNS. Sagittal sections from different levels show that the majority of GFP signal is
localized to the areas in the mid brain and hindbrain: the colliculi- both superior and inferior,
pons, suprachiasmatic nucleus, cerebellum and the medulla. Several nuclei containing cell bodies
of GFP positive cells are restricted to the colliculi and several areas of the pons.
In the next experiment, sections were stained with DAPI; a nuclear stain to identify the
glycinergic cellbodies in these glycine rich areas and Figure 6 shows the presence of glycinergic
cell bodies in the brainstem and cerebellum areas.
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Figure 5: 10X saggital Section 109 (30 µm, paxinos mouse brain atlas 5 Ed.) of
eGFP- GlyT2 mouse brain. B: Nissl stain
Abbreviations: Cx: Cortex, Thm: Thalamus, CO: Colliculi, SC: Superior
Colliculus,IC: Inferior colliculus, Pn: Pons, SOC: Superior Olivary nucleus complex,
Mdl: Medulla, Cbm: Cerebellum.
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Figure 6. A) 10X saggital section 109 (30 µm) of e-GFP-GlyT2 mouse brain stained with
DAPI(nuclear stain).
B) 10X image of cerebellum and Brainstem and Superior Olivary complex.
C) 40X image of Cerebellum Brainstem and Superior Olivary nucleus indicating the
presence of glycine- rich (green) areas and cell bodies (blue).
Glycine- rich fibers are visible in the brainstem.
Abbv: Cx: Cortex, SOC: Superior Olivary Complex
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From the above experiment, it is pretty clear that there appears to be a rich network of
glycinergic fibers that appear to criss-cross the brainstem area along with a large number of cell
bodies, which seem to be positive for glycine. While these findings not only confirm the already
known truth about abundant glycine in the caudal areas of the nervous system but also open
avenues for further research about the presence of glycine in new areas of the brain such as the
colliculi as well as numerous cell bodies (GFP-positive) in the pons and the superior olivary
complex area.
Following these preliminary studies, I decided to focus on identifying expression of the
GlyT2 in these areas. The first step was to optimize the GlyT2 antibody dilution in order to
visualize its distribution in areas such as the pons and the inferior colliculus. Optimization
experiments, vigorous testing and comparisons with stringent controls such as no primary
controls and pre-adsorption studies led to the successful visualizing of GlyT2 staining using the
following dilution of antibodies: 1:2000 primary GlyT2 Ab (rabbit) and secondary Ab antirabbit 1:10K Alexa 488. In order to visualize neuronal cell bodies, NeuN antibody (mouse) was
used, at a dilution of 1:2000 and secondary antibody, Alexa 647 (anti-mouse; dilution?).
Figure 7 shows the presence of cell bodies that test positive for GlyT2 (stained yellow in
the merge column). The above experiment was repeated using the same section but incorporating
NeuN in order to identify neurons in the inferior colliculus. Figure 8 shows the presence of some
cells that test positive for NeuN as well as for GlyT2 indicating that these are glycinergic
neurons found in the inferior colliculus area.
The expression of GlyT2 in the inferior colliculus is a novel result and holds significance with
exciting possibilities for further studies, which will be elaborated upon in the Discussion section
of this thesis.
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Figure 7: Immunostaining of GlyT2 in the IC region of saggital section 109 (30 µm)
e- GFP- GlyT2 transgenic mouse brain.
Top panel: No primary control (Tissue incubated with blocking solution for
Primary incubation, secondary antibody: Cy3 1:10,000). Middle panel: Lower
magnification, GlyT2 (red) Lower panel: Higher magnification, GlyT2 (red).
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Figure 8: Immunostaining of GlyT2 neurons in the IC region of saggital section 109 (30
µm) e- GFP- GlyT2 transgenic mouse brain.
Panel A & B show lower (10X) and higher (40X) magnification images of the IC neurons
(stained with NeuN, pink) staining positive for GlyT2 (Red),
Some of these GlyT2 positive neurons co- localize with glycine- rich cell bodies (yellow).
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2.2.4 GlyT2 expression in the brainstem:
Studies performed in rats, guinea pigs, bats and cats have indicated the presence of
glycine in the lower auditory areas of the brainstem region such as the superior olivary complex
(Aoki E, 1988) (Adam, 1979) (M. Merchána, 2005). It is understood that glycine plays an
important role in modulating inhibitory neurotransmission in conjunction with GABA (Coleman
JL, 2011). With this knowledge it is reasonable to presume that there is a probability of finding
expression of glycine transporters in these auditory nuclei areas as well since almost all of them
project to the inferior colliculus where the expression of GlyT2 has already been shown
previously in the results. Figure 9 depicts the expression of GlyT2 in the brainstem in a saggital
section of the transgenic mouse brain whereas Figure 10 depicts the expression of GlyT2 in the
lower auditory nuclei of the brainstem such as the MVPO, LVPO, VCA, and other regions.
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Figure 9: Immunostaining of GlyT2 neurons in the BRAINSTEM region of saggital
section 109 (30 µm) e- GFP- GlyT2 transgenic mouse brain.
A) Nissl staining B) GFP fluroscence (green)
C) GlyT2 positive neurons observed in the Pons region of the brainstem. (GlyT2- red,
NeuN- Pink, Merge- yellow)
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Figure 10: Immunostaining of GlyT2 neurons in the BRAINSTEM region, coronal
section 77 (paxinos mouse brain atlas 5th Ed., 30 µm) e- GFP- GlyT2 transgenic
mouse brain. A) Nissl staining of section 77. B) GFP (green) signal, C and D) GlyT2
staining (red) visualized in the VCA (white square), MVPO (yellow square). Neurons
are stained with NeuN (pink).
Abbv: 4/5 Cb: Cerebellar lobe, DC: Dorsal coclear nucleus, VCA: Ventral Cochlear
nucleus, MVPO, LVPO: Medial and lateral periolivary nuclei, LSO: Lateral superior
olive, 4V: Fourth ventricle.
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As observed in figure 5, there seem to a rich network of putative glycinergic cell bodies
and fibers in the brainstem area especially in the pons area as well areas comprising the superior
olivary complex such as the lateral periolivary nucleus, medial periolivary nucleus and the
ventral periolivary nucleus (LVPO, MVPO, VLPO respectively). Hence, there was a high
probability of identifying GlyT2 expression in these areas as well. Figure 9 represents the
expression of GlyT2 in the pons as visualized in a saggital section while Figure 10 shows the
expression of GlyT2 positive neurons in the cochlear nucleus (Ventral area, VCA) as well as the
lateral periolivary nucleus in the coronal section 78.
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CHAPTER 3: DISCUSSION
There has been a steady increase in studying glycine as a neurotransmitter and the various
components involved in mediating glycinergic neurotransmission. The duality of glycine’s role,
as an inhibitory neurotransmitter at glycinergic synapses and as a modulator of excitatory
glutamatergic neurotransmission mediated by NMDA (N-methyl-D-aspartate) receptors, makes
it an interesting target for research and especially for designing therapeutic interventions against
a host of ailments such as schizophrenia and alcohol and drug addiction to name a few (Johnson
and Ascher, 1987).
The glycine transporters GlyT1and GlyT2 play an important role in regulating the
glycinergic neurotransmission by controlling the amount of glycine available at the synapse and
by promoting its re-uptake to ensure its repackaging into the synaptic vessels to sustain a new
round of inhibition (Eulenberg V, 2005) (Eulenburg V, 2010). There is no surprise, therefore,
that both the transporter proteins are linked to a number of disorders that are on the rise today
such as schizophrenia, alcohol and drug addiction, hyperekplexia, epilepsy, breathing and muscle
disorders. (Harvey R, 2008) (Sager JJ, 2011)
While GlyT1 is definitely better studied of the two transporters, the focus of this research
is GlyT2, the lesser known but highly interesting glycinergic transporter that is solely devoted to
the task of clearance of glycine from the synapse back into the pre-synaptic neuron to make it
available for repackaging into synaptic vesicles. GlyT2 is exclusively neuronal, found
abundantly in the caudal areas of the CNS such as brainstem, cerebellum and spinal cord. Its
importance can be gauged by the fact GlyT2-/- mice do not survive more than 2 weeks after birth
and show poor growth and reflexes, acute respiratory distress, muscle spasticity etc. (Gomeza. J,
2003). Mutations in the GlyT2 gene also give rise to hyperkplexia aka Startle’s disease. GlyT2 is

36

not just implicated in disorders but is an attractive therapeutic target for therapies against chronic
pain as well as the development of effective analgesics and anesthetics. (Dohi, 2009) (Masson J,
1999; Coleman JL, 2011) (Davies, Chung et al. 2010).
Because of an ever-increasing interest in GlyT2, it is a highly exciting area of research
and presents some unique aspects to study. As highlighted in figures 1 & 2, the presence of a
long 201 amino acid tail at the N-terminus, a feature not shared with any other member of the
SLC6 family of neurotransmitter transporter (including GlyT1), is the focus of this research.
Previous studies done using dopamine, serotonin transporters as well as receptors like AMPA
has shown that the N-terminus of these proteins often acts as a binding site for a number of
proteins that are implicated in assisting the anchorage of these receptors and transporters at the
plasma membrane or proteins that are involved in and are a part of signaling cascade that
regulate the assembly, recycling and functions of the transporters. (Eriksen J, 2010) (Lee K,
2004).
Based on these studies, it is reasonable to hypothesize that this long N-terminal tail of
GlyT2 could serve as binding site for proteins that can have an impact on the anchorage,
distribution and/or recycling of the transporter. In order to test this hypothesis, I performed a
yeast two-hybrid assay that is a fast, convenient and fairly reliable technique to identify potential
interacting proteins. To accomplish this, a fusion protein of the N-terminal domain of GlyT2 Nterminal expressed in yeast plasmid pGBKT7-53 was constructed and rigorously tested by
expressing this fusion protein in the yeast strain AH109 and by performing a western blot to
conform its expression in the yeast strain as shown in Figure 3. Once it was ascertained that the
fusion protein is abundantly expressed and isn’t toxic to the yeast strain, the N-terminus of
GlyT2 was used as ‘bait’ to screen a normalized human brain cDNA library (Clontech Inc.) to
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identify potential interactors. The transformed yeast strain was plated on low stringency (-Leu/Trp) plates and high stringency (-Ade/-leu/-Trp/-His) plates to identify true positive interactions.
By this screen, 74 clones were obtained on the high stringency plates and were utilized for
identifying the interacting proteins. Only the clones growing on high stringency media were
identified (indicating higher degree of true interactions) and studied further. Further, as shown in
Figure 4, drop tests were performed for clones 1 to 26 to test the validity of our results and to
identify clones that grow better (hence indicating better chances of positive interactions). Once
it was confirmed that all the 26 clones are growing on the high stringency SD media, the
plasmids from clones 1 to 26 were recovered from these transformed yeasts by the Yeast plasmid
recovery kit protocol (Clontech). These recovered plasmids were then transformed in competent
E.coli bacterial cells (Agilent technologies, US) and the purified DNA was sequenced to reveal
their identity as listed in Table 1.
Out of the 26 clones that were sequenced, most of the potential interactor proteins are
cytoskeletal proteins (MAP2, CKAP5, MAP Tau etc), some involved in signaling (PTPN2, Cam
Kinase II) to name just a few. This validates the hypothesis that the N-terminus of GlyT2 is an
important binding site for a number of proteins. Moreover, pull down assays done in the lab by
Dr. Luciana Gentil, a former Research Associate in theMiranda Lab also led to the identification
of cytoskeletal proteins such as actin, beta tubulin and NSF (N-ethyly amide sensitive factor, a
protein involved in fusion of synaptic vesicle with the plasma membrane), which provides
independent corroboration of the yeast two hybrid results. Currently, studies are underway that
would confirm these interactions in vitro and in vivo thus providing more insights into the nature
of these interactions and their impact on the activity of the transporter. Some of these proteins
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could serve as potential therapeutic targets for alleviating some of the GlyT2 associated disorders
listed previously.
The second important aspect of this research has been the identification of GlyT2 in
glycine rich areas of the brain. As mentioned previously, GlyT2 is exclusively neuronal and
hence is a reliable marker for glycinergic neurons. Even though it can be inferred that the
expression of GlyT2 would coincide with the presence of glycine, there hasn’t been much
research done in identifying exclusively glycinergic areas in the CNS. For instance, it is well
know that dopaminergic cells are found in substantia nigra and project to areas such as the
ventral tegmental area, nucleus accumbens, and striatum. Not much is known about the presence
of glycinergic cell bodies or their projections into different regions of the brain. This knowledge
could potentially lead to an excellent understanding of disorders associated with glycinergic
neurotransmission and pave the way for therapeutic intervention against these complications.
The identification of these glycinergic cell bodies could lead to identification of glycinergic
circuits that can be amenable to optogenetic manipulations and provide better insights into
understanding glycinergic inhibitory neurotransmission.
The use of the transgenic mouse model, expressing GFP under the influence of GlyT2
promoter (eGFP- GlyT2), kindly provided by Dr. H. U. Zeilhofer, University of ErlangenNurnberg, Germany (Zeilhofer et al., 2005), gives an excellent understanding of the distribution
of GlyT2 in the CNS. The animals were perfused and their brains were sectioned in a sagittal
plain, mounted in glycerol to visualize the fluorescence, and alternate sections were used to
perform Nissl in order to identify anatomical landmarks and cytoarchitecture of the brain tissue.
Figure 5 confirms the expression of glycine in the caudal areas of the nervous system like the
brainstem, cerebellum and the spinal cord and interestingly, reveals presence of glycine in the
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mid brain areas specifically the colliculi. Subsequently, some of these sections were stained with
DAPI (1:1000) in order to localize the glycinergic cell bodies in areas rich in GFP signal (Figure
6) and it is clear that there are abundant glycinergic cell bodies distributed all over the areas of
the hind brain such as the cerebellum, pons, various nuclei of the superior olivary complex like
the LSO, MVPO, LVPO to name a few. But the presence of a rich network glycinergic fibers and
interspersed among them, a few cell bodies in the colliculi is an important discovery that could
highlight previously neglected role of glycine in this area.
The inferior colliculus is an important component of the auditory pathway as it receives
ascending projections from nearly all brainstem auditory nuclei, and also from the contralateral
inferior colliculus. It acts as a relay station and projects to the median geniculate nucleus, which
in turn carried information to the auditory cortex (Coleman JL, 2011) (Adam, 1979) (M.
Merchána, 2005). The inferior colliculus is the responsible for integrating multi-modal sensory
perception and plays an important role in detection of pitch, mediating startle response and
vestibulo-ocular reflex etc. Most of the studies about teasing out the role of the inferior colliculus
and its projections have been done using animals such as bats, cats and gerbils etc. and there are
virtually no studies using mouse models. Presently, there is a renewed interest in the circuitry of
the inferior colliculus and studies are being undertaken to decipher the source of auditory
hallucinations (hearing noises), which are a vivid feature of Schizophrenia (Shergill SS, 2000).
From the previously published work, it is clear that the inferior colliculus is rich in fibers that are
mostly GABAergic and that the inhibitory inputs received from the brainstem nuclei to the
inferior colliculus are also predominantly GABAergic and glycinergic (M. Merchána, 2005).
Further, results shown in figures 5 and 6 highlight the need to study the presence of glycinergic
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cell bodies in this area, which could provide some clues about the projections of the glycinergic
fibers that are so abundant in this region of the brain.
The immediate goal was to identify whether these IC cell bodies are neuronal or glial and
this was accomplished by identifying expression of GlyT2 in this area of the mouse brain. The eGFP- GlyT2 transgenic animal is an excellent model for these studies but there has been a
concern about the leaky expression of GFP in some areas. Hence, in order to overcome the leaky
expression of the GFP and to accurately identify GlyT2 positive neurons, a highly specific
GlyT2 polyclonal antibody was produced in the lab, which was exhaustively optimized in order
to visualize GlyT2 in the brain. Figure 7 shows the presence of a small number of cell bodies that
test positive for GlyT2 in the CIC as compared to a no primary control. Some of the populations
of cells that don’t stain with GlyT2 do stain positively for GAD67 (a marker for GABA,
unpublished data from the Miranda Laboratory) thereby highlighting the presence of a mixed
population of cells in this region, which is in confirmation with previously published studies.
The above experiment was repeated using the same section but incorporating NeuN, a
neuronal marker to confirm the presence of glycinergic neurons in the inferior colliculus. As
seen in Figure 8, there exists a distinct population of cell bodies that test positive for NeuN as
well as for GlyT2 confirming that these are glycinergic neurons found in the inferior colliculus.
This is a novel result and, coupled with the knowledge that there is an abundant network of
glycine- rich fibers in this area, it is reasonable to speculate that some of these fibers must be
ascending projections from the lower areas of the brainstem auditory nuclei just as there could be
a population of fibers that must be projecting from the inferior colliculus to the median
geniculate nuclei and to the Auditory cortex. While tracing these projections is beyond the scope
of this research, it was our intention to identify the expression of GlyT2- positive in the
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brainstem auditory nuclei, which, as mentioned previously, project to the IC. Figure 9 shows the
presence of a distinct population of neurons in the pons area, which test positive for GlyT2.
Studies done using GAD67 have also indicated the presence of GABAergic neurons in this area
(data not shown) thereby confirming what is already known about the presence of GABA in the
pons. Figure 10 shows the expression of GlyT2 in the lower auditory nuclei of the brainstem
such as the MVPO, LVPO, and VCA etc. as seen in a coronal section of the transgenic mouse
brain. Moreover, as observed in the inferior colliculus area, it seems that there is a rich network
of glycinergic cell fibers in the brainstem especially in the pons area as well. The possibility of a
distinct population of glycinergic neurons amongst these mixed population of glycine/
GABAergic neurons is a novel result and points to the importance of assisting GABA in finetuning various aspects of auditory information.
It is interesting to note that this research provides evidence for the existence of GlyT2
positive neurons in not just the inferior colliculus but also in some brainstem nuclei like the
cochlear nuclei and the periolivary complex. These findings can pave the way for future neuronal
tracing projects that will help identify the target areas of the glycinergic neurons of the inferior
colliculus, which can be useful in identifying the important functions associated with such
pathways. As mentioned previously, mutations in the GlyT2 can give rise to hyperekplexia
characterized by exaggerated startle response to acoustic or visual stimuli and it would be
interesting to know if there is any possibility of isolating the glycinergic circuit that contributes
to this condition. Preliminary tracing experiments done in this study using the transgenic mouse
model (eGFP- GlyT2), using FluroGold as a retrograde tracer, have confirmed the existence of
projections between the brainstem auditory nuclei and the IC and also identified the expression
of GlyT2 in both the areas (unpublished data, Miranda Lab). Therefore, it would be interesting to
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study the role of the transporter in mediating these important auditory functions and to identify it
as a potential target for designing therapeutic interventions for a host of complications previously
mentioned. Currently, there are a number of fMRI studies being done in human subjects that are
trying to understand the role of various auditory nuclei including the IC in contributing to the
auditory hallucinations that are a distinct hallmark of schizophrenia and other psychotic
conditions.
This research brings to light certain important aspects of GlyT2 and its important role in
inhibitory neurotransmission.
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